Article
The CYP2A6*4 allele is determinant of S-1 pharmacokinetics in Japanese patients with non-small-cell lung cancer.
Clinical pharmacology and therapeutics - 1 Apr 2008
Kaida Y, Inui N, Suda T, Nakamura H, Watanabe H, Chida K
Abstract excerpt
S-1 is an oral fluorouracil anticancer drug that contains the 5-FU prodrug tegafur. Tegafur has been shown to be converted enzymatically to 5-FU to exert its antitumor effect, and this conversion is principally catalyzed by CYP2A6. Forty-six non-small-cell lung cancer patients were enrolled. The frequencies of the CYP2A6*4C, CYP2A6*7, and CYP2A6*9 alleles were 17.4, 19.6, and 15.2%, respectively. In the S-1...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.